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1. Introduction
Russia's overall disease burden attributable to substance use is one of the highest in the 
world (1). It is among the top three countries (together with China and the USA) with the 
largest estimated populations of persons who inject drugs (PWID) (2). Injection drug use is 
the main driver of HIV transmission in Russia (3, 4), a country where HIV incidence is 
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steadily increasing. This same trend is occurring throughout parts of Eastern Europe where 
substance use is widespread and stands in contrast to the decline or stabilization of HIV 
incidence currently seen in other parts of the world (5), reflecting a strong relationship 
between injection drug use and HIV transmission. Estimates from 2017 suggest 30.4% 
(17.9-43.0%) of all PWID in Russia were living with HIV (6). Despite the country's fast-
growing HIV epidemic, access to prevention and harm reduction services, such as needle 
and syringe exchange programs and opioid agonist treatment are limited and non-existent, 
respectively (4). Further, available statistics suggest the majority of Russian adults (63%) 
living with HIV are not on antiretroviral treatment (ART) (7). Numerous barriers prevent 
access to treatment, including the multiple steps required to enter into HIV care, 
discrimination towards people living with HIV (PLHIV) overall, and conservative legislation 
placing restrictions on same-sex and other non-traditional relationships, drug use and sex 
work (4, 8). Effective, evidence-informed prevention strategies are urgently needed in Russia 
to prevent both HIV acquisition and transmission. Understanding the country's HIV 
dynamics and patterns of transmission and acquisition are essential for designing approaches 
to reach key populations, including PWID and their sexual partners.
Globally, there are more male than female PWID (4) but available data suggest that among 
PWID, women have a higher HIV prevalence in many settings (9), including Eastern 
Europe. A 2012 meta-analysis including data collected from 128,745 PWID, drawn from 
117 studies in 14 countries (including Russia) found a modest but significantly higher HIV 
prevalence among female PWID, relative to male PWID (OR=1.18; 95% CI: 1.10-1.26) 
(10). Many possible explanations exist for elevated risk for HIV infection among women 
relative to men, irrespective of drug use behaviors. Clear biological mechanisms underlie the 
differential outcomes of HIV infection in women and men. For example, male-to-female 
HIV sexual transmission is more efficient than female-to male transmission because HIV-1 
infected women have lower infectious potential (11). Additionally, sex hormones in women 
contribute to enhanced susceptibility by affecting the vaginal mucosa. It is hypothesized that 
women have lower viral reservoirs (11). It is also widely recognized that sociocultural 
factors, particularly as they relate to attitudes and practices surrounding sexual behaviors 
(e.g., norms dictating it is acceptable for men, but not women, to have multiple sex partners) 
contribute to disparities in HIV infection and transmission between men and women, in the 
context of heterosexual partnerships. Further, gender-based inequalities (e.g., intimate 
partner violence; engagement in sex work and/or transactional sex; women's lower wages, 
compared to men; and less empowerment to negotiate condom use) prevent many women 
from protecting themselves and/or their partner(s) against HIV infection (10).
Less is known about the elevated risk for HIV infection and transmission among women 
(relative to men) who inject drugs. It has been found that unsafe injection practices (e.g., 
sharing used needles) and condomless sex heighten HIV infection risk among all PWID, but 
evidence suggests women who inject drugs are disproportionately more likely to engage in 
these behaviors, compared to men (12). Despite these findings, female PWID are often 
underrepresented in research with drug users and in studies on access to HIV care (12). 
Evidence-based prevention measures aimed at PWID are urgently needed and have been 
specifically called for in Russia, where PWID account for the largest proportion of new HIV 
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diagnoses, relative to any other risk group in the country (13) and where evidence is limited 
on gender differences in HIV risk behaviors among PLHIV who have ever injected drugs.
A prior study (14) with women who inject drugs in St. Petersburg found 64% were HIV-
positive and, in the past year, over 50% had two or more sexual partners, 40% transacted 
sex, 40% had condomless sex and 40% shared injecting needles. Transactional sex and 
sexual violence (reported by 12%) were both associated with increased injection drug 
equipment sharing and violence was associated with increased condomless sex. A second St. 
Petersburg study (15), conducted with male and female PWID living with HIV found 
internalized stigma surrounding HIV and drug use was correlated with poorer health 
outcomes and lower likelihood of service utilization. Although this study did not examine 
gender differences in these relationships, other research suggests that, compared to men, 
women who use drugs experience more stigma related to gendered cultural norms which 
contributes to increased risk for negative HIV outcomes (12).
“Women-specific” research and prevention approaches have been called for to better 
understand the true context in which drug-using women experience health risks, and to 
design programs that account for the social, micro, and macro levels of women's lives (12). 
Further, it is imperative that efforts be placed on developing gender-specific strategies for 
conducting research and programs to understand and reduce female PWID's risk for both 
HIV acquisition from (i.e., among HIV-negative PWID) and transmission (i.e., among HIV-
positive PWID) to sexual and injection drug use partners. Although a developing body of 
research informs our ability to design gender-tailored programs to prevent HIV infection 
among HIV-negative female PWID (e.g., discouraging needle sharing) (14), less is known 
about how to effectively prevent HIV transmission by HIV-positive PWID to HIV-negative 
sexual partners or injection drug use partners.
We aimed to assess the association between female gender and drug risk behaviors (e.g., 
sharing injection drug equipment with others) and sex risk behaviors (e.g., condomless sex) 
among a population of HIV positive men and women who had ever injected drugs in St. 
Petersburg, Russia. Recognizing injection drug use as a chronic condition, and that most 
PWID go through repeated periods of injection cessation and relapses during their injection 
careers (16, 17), we included participants who reported past month injection drug use and/or 
injection drug use prior to their HIV-positive diagnosis. Alcohol use prior to sharing 
injecting equipment and surrounding sex were secondary outcomes in our analysis because 
alcohol consumption overall (18) including by PLHIV (19) has been associated with 
significantly higher drug and sex risk behaviors that heighten vulnerability for HIV 
acquisition, as well as transmission to others (4). Additionally, some of the most risky 
patterns of drinking (i.e., consuming alcohol at amounts that increase the risk of health or 
social consequences) (20) have been observed in Russia and Ukraine. Based on what has 
been found in other studies in Russia and other settings, we hypothesized that among 
Russian PLHIV who had ever injected drugs, women would have higher odds of engaging in 
high risk drug use, sexual behaviors, and use of alcohol prior to sex or injecting drugs, 
relative to men.
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2. Methods
2.1 Study Design and Sample Characteristics
This study involved secondary analysis of data from the Russia ARCH cohort, which is part 
of the three site Uganda, Russia, Boston Alcohol Network for Alcohol Research 
Collaboration on HIV/AIDS (URBAN ARCH) Consortium. Russia ARCH is an 
observational prospective cohort study conducted to assess the longitudinal association 
between alcohol consumption and biomarkers of microbial translocation and inflammation/
altered coagulation, which also encompasses a nested randomized controlled trial (ZINC) 
aimed at assessing the efficacy of zinc supplementation on markers of inflammation.
A sample of 351 Russia ARCH participants were recruited into the study between 
November 2012 and June 2015 from clinical HIV and addiction care sites, non-clinical sites, 
and via snowball recruitment in St. Petersburg. Eligibility criteria for inclusion in the cohort 
included the following: 18-70 years old; documented HIV-infection; documented ART-naïve 
status; the ability to provide contact information for two contacts to assist with follow-up; 
stable address within St. Petersburg or districts within 100 kilometers of St. Petersburg; 
possession of a home or mobile phone. The current analysis was restricted to people who 
had ever injected drugs, defined as individuals who reported a history of injection drug use 
prior to HIV diagnosis, or past 30-day injection drug use at study visit. Participants were 
excluded from the cohort if they were not fluent in Russian or had a cognitive impairment 
resulting in inability to provide written informed consent. Eligibility was verified and 
informed consent was obtained. Participants provided a blood sample and were administered 
an interview assessment. Institutional Review Boards of Boston University Medical Campus 
and First St. Petersburg Pavlov State Medical University approved this study.
Data for the current analysis come from assessments conducted at baseline, 12- and 24-
months post enrollment.
At baseline the following surveys were administered: Demographics (21); Sex Behaviors 
(22); Sexual Partners; HIV Risk Categories (23); Alcohol 30 Day Timeline Follow Back 
(24), (25); Drug Use (modified Risk Behavior Survey) (26, 27), (28). The 12- and 24-month 
ARCH assessments contained the same sections of the baseline assessment with the 
exception of the HIV Risk Categories section. Most sections of the baseline and follow-up 
assessments were conducted by trained research assessors, administered in Russian and took 
between 60 and 90 minutes. Particularly sensitive sections of the assessment (including Sex 
Behaviors; Sexual Partners; and HIV Risk Categories) were self-administered by the 
participant.
2.2 Measures
The main independent variable for this study was female gender. Gender was self-reported 
as male or female. We did not assess other gender categories. The two primary dependent 
variables of interest were sharing of injecting equipment in the past 30 days and condomless 
sex in the past 90 days. Condomless sex was defined as vaginal or anal sex (meaning a penis 
was inserted into the vagina and/or anus) with any sexual partner without the use of a 
condom or other protective barrier. Three secondary outcomes of interest were also 
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examined, including alcohol use prior to sharing injecting equipment in past 30 days, 
alcohol use before or during sex in past 90 days, and reporting of both of the primary 
dependent variables (i.e., drug equipment sharing [in the past 30 days] and condomless sex 
[in the past 90 days]).
The following were selected as covariates for inclusion in the adjusted models, due to their 
potential confounding effects: age, education (less / greater than 9th grade), income (less / 
greater than the median of the sample), partnered status, and recent ART use at follow-up. 
We also controlled for recent ART use at follow-up using data from participants' responses 
to the following question about ART use at the 12 month and 24 month follow-up, “in the 
last 6 months, have you taken anti-retroviral medications for treating HIV?” Covariates were 
selected based on clinical knowledge and the literature.
Partnered status was a 3 level covariate with the following categories: not partnered, 
partnered HIV discordant partner (i.e., uninfected partner), and partnered HIV concordant 
partner (i.e., HIV-positive partner). There were 21 observations (from 17 unique subjects) 
over the course of the study (7 at baseline, 9 at 12 months, and 5 at 24 months) whereby a 
participant reported they did not know the HIV status of their partner. Data from these 
observations were excluded from the analyses. Partner denoted being married, in a domestic 
partnership/living with a partner, or in a long-term relationship (duration of marriage or 
long-term relationship was not measured). Also measured at baseline were median income 
in Russian Rubles with interquartile range (IQR), mean CD4 count (±5 SD), heroin or other 
opioid (including codeine, china white, methadone, fentanyl, Krokodil, Khanka) use in past 
30 days, and cannabis use in past 30 days. Since measures for past month heroin or opioid 
use did not distinguish the mode by which the drug was taken, we included data from a 
question assessing any injection drug use in the past 30 days (yes/no). Those who indicated 
past 30 day injection drug use were asked to specify the type of drug injected (heroin and 
stimulants; only heroin; only stimulants; neither heroin nor stimulants). Heavy alcohol use in 
past 30 days was measured via the 30-day Timeline Followback Method and defined as 
heavy if meeting NIAAA at-risk drinking amounts (i.e., ≥5 drinks in a day for men and ≥4 
drinks in a day for women) (28). Because involvement in transactional sex was associated 
with injection risk among women in a recent St. Petersburg study (14), we measured 
whether both male and female participants reported having given sex to a partner, received 
sex from a partner or both given and received sex to/from a partner in exchange for money, 
alcohol, drugs, or other things in the past 12 months.
2.3 Statistical Analysis
We assessed baseline frequencies of demographic characteristics, covariates, CD4 count, 
heroin or other opioid use, any injection drug use (and type of drug injected), cannabis use, 
heavy alcohol use and transactional sex, overall and by gender. For descriptive purposes, we 
assessed differences between male and female participants at baseline using chi-square and 
Fisher's exact tests for categorical variables, and t-tests and Wilcoxon rank-sum tests for 
continuous variables. We assessed baseline, 12 month and 24 month follow-up frequencies 
for the primary and secondary outcomes and 12 month and 24 month follow-up frequencies 
for ART use in the past 6 months. To account for the correlation from using repeated 
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observations from the same study participants, separate generalized estimating equations 
(GEE) logistic regression models were used to evaluate the association between gender and 
each of the binary outcomes controlling for potential confounders. An independence 
working correlation was used and robust standard errors from the GEE approach are 
reported. Odds ratios (ORs) and 95% confidence intervals (CIs) are presented from the 
logistic regression models. Preliminary unadjusted logistic regression models were initially 
fit for each outcome. We then fit a partially adjusted model controlling only for the 
demographic covariates specified above (i.e. age, education and income). Lastly, we fit the 
final, fully adjusted model controlling for demographic covariates and marital/partner status 
(non-partnered, partnered HIV discordant, partnered HIV concordant) and respondents' 
reports of ART use in the past 6 months, as recorded at the 12 and 24 month follow-up 
interviews. A posthoc sensitivity analysis was performed excluding observations from 
participants who used ARTs. All analysis was done using the statistical package SAS 9.3.
3. Results
At baseline the sample included 291 HIV-positive participants from the Russia ARCH 
cohort who had ever injected drugs. The mean age at baseline was 33 (SD ±5) years and 
most participants (75%, 217/291) were male; 25% (74/291) were female and 78% (228/291) 
had more than a 9th grade education. More men (49%, 107/217) than women (31%, 23/74) 
were employed. The monthly median income was 20,000 Rubles (IQR: 5,000-30,000), 
approximately $550 USD at a conversion rate averaged over the time of survey 
administration (November 2012 – June 2015), and women appeared more likely than men to 
have earnings below the research sample's median income (68% [50/74] versus 44% 
[94/217] p<0.01). Approximately half of the participants (149/291) were not married or in a 
partnership; 31% (91/291) were in a concordant relationship with a partner who was living 
with HIV and 18% (51/291) were in a discordant relationship with an HIV-negative partner. 
Women were more likely than men to be in an HIV concordant relationship (female: 50% 
[37/74] vs. male: 25% [54/217]). Men were more likely than women not to be partnered at 
all (male: 57% [124/217] vs female: 34% [25/74]).
The mean CD4 cell count in this baseline ART-naïve population was 525 (SD ±306). In 
terms of drug use, 41% (118/291) of respondents reported past 30 day heroin or other opioid 
use. Injection drug use, specifically, was reported by 44% (127/291), among whom most 
injected heroin (76%, 96/127), followed by heroin and stimulants (14%, 18/127), stimulants 
only (8%, 10/127) and neither heroin nor stimulants (2%, 3/127). Cannabis use in the past 
30 days was reported by 17% (48/291) and 70% (205/291) reported heavy alcohol use in the 
past 30 days.
Most participants (86%) reported no form of transactional sex in the past 12 months. The 
most common transaction was reported by men (14%) as having given money, drugs or 
alcohol in exchange for sex. We did not measure the type of partner (i.e., regular female 
partner, same-sex partner, sex worker) involved in this exchange. No women reported giving 
something for sex and all other forms of transaction were reported by less than 5% of the 
sample, see Table 1.
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Table 2 shows the proportion of participants (overall and by gender) who reported on the 
primary and secondary outcomes of interest at baseline, 12 and 24-month follow-up. High 
risk sex behaviors (i.e., condomless sex in the past 90 days and alcohol use before or during 
sex) were more commonly reported than drug risk behaviors (i.e., sharing drug equipment in 
the past 30 days and alcohol use prior to sharing). Although Table 2 only descriptively 
presents the longitudinal frequencies of each outcome, it is noteworthy that – relative to 
male participants - a higher estimated proportion of female participants reported engaging in 
every risk behavior at every time point with the exception of past month alcohol use before 
sharing equipment, as reported at the 12 month follow-up. In general, it appears that there 
were not substantial changes over time across the various outcomes presented in Table 2. 
ART use appeared to increase from 12 to 24 months, particularly among men. All 
participants were ART-naïve at baseline but 17% and 35% reported having taken ART in the 
past 6 months at the 12 and 24 month follow-up visits, respectively.
Relative to male participants, female participants had significantly higher odds of reporting 
both primary outcomes, sharing injecting equipment in the past 30 days (OR=1.92; 95% CI: 
1.16-3.18, p=0.01) and condomless sex in the past 90 days (OR=2.65; 95% CI: 1.69-4.15, 
p<0.01) in the unadjusted models. After controlling for demographic covariates, partner 
status and ART use, the association between female gender and sharing injecting equipment 
was no longer significant. Female gender remained significantly associated with condomless 
sex in the past 90 days, even after controlling for demographics (aOR=2.73; 95% CI: 
1.67-4.48, p<0.01) and additionally, both partner status and ART use (aOR=1.91; 95% CI: 
1.12-3.23, p=0.02), Table 3. The conclusions from posthoc sensitivity analyses excluding 
observations from participants who used ARTs were consistent with the main analyses for 
all 5 outcomes (data not shown).
The unadjusted odds of one of the secondary outcomes was higher for female participants 
than male participants: reporting both drug equipment sharing and condomless sex 
(OR=3.03; 95% CI: 1.65-5.63, p<0.01). After controlling for demographic covariates, 
female gender remained statistically significant for the outcome, reporting both injection 
equipment sharing and condomless sex (OR=2.45; 95% CI: 1.33-4.52, p<0.01). In the final 
fully adjusted model, where we controlled for demographics as well as the 3 level partner 
status covariate and ART use, the association between female gender and reporting both 
injection equipment sharing and condomless sex was no longer significant. No significant 
association was found in any of the models between female gender and alcohol use prior to 
sharing equipment in the past 30 days, or prior to or during sex in the past 90 days, see Table 
3.
4. Discussion
Among a cohort of PLHIV in Russia who have ever injected drugs, we detected a 
statistically significant association between female gender and condomless sex in the past 90 
days, even after controlling for the potentially confounding effects of demographics, partner 
status, and ART use. Although we observed notable associations between gender and other 
outcomes, including sharing drug equipment, alcohol use prior to sharing, and both drug 
equipment sharing and condomless sex, the results were not statistically significant, possibly 
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due to limited power given the relatively small number of women in the study. It is also 
notable that nearly all risk behaviors, other than alcohol use prior to sharing, appeared to be 
more commonly reported among women compared to men.
The increased odds of substance using women having condomless sex, compared to men, 
has been previously documented in multiple settings (29), including St. Petersburg, Russia 
(30). Prior research from St. Petersburg also found partnership status (i.e., HIV concordance 
versus HIV discordance) to be a major factor in PWID's decision-making process about 
whether to engage in condomless sex with their partner (31). In our study, more participants 
reported being in HIV concordant partnerships (versus HIV discordant partnerships) which 
could explain why such a high proportion of respondents engaged in condomless sex. 
Regardless, female participants had higher odds of reporting condomless sex, irrespective of 
their partner's HIV status, posing risk for HIV transmission in this population. Further, the 
preventive health benefits of HIV-positive persons using a condom or other protective barrier 
during vaginal or anal sex are indisputable, regardless of their partner's HIV serostatus. 
These results are particularly concerning in light of recent research suggesting heterosexual 
transmission of HIV is increasing in St. Petersburg, and may overtake injection drug use as 
the primary mode of transmission (32), and suggest a need for a comprehensive, multi-
pronged response which should include “treatment as prevention” (TasP) (i.e. ART for HIV-
positive partners to achieve viral suppression and reduce transmission) (33) and pre-
exposure prophylaxis (PrEP) for HIV-negative partners (34). Interventions promoting 
condom usage are also warranted. However, our finding that women were less likely than 
men to use condoms under all circumstances implies that such approaches must be designed 
to account for the social, micro, and macro contexts of women's lives. At the relationship 
level, alcohol use prior to sex was common and may have interfered with condom decision-
making around the time of the sexual event. Connecting women (and their partners) to 
alcohol harm reduction programming could help to lessen their collective risk for HIV 
infection and transmission (35).
Our findings support the value of implementing multi-level interventions and also imply that 
TasP is a high-yield approach with potential to reduce the risk of transmission with 
condomless sex, as well as provide a multitude of other health benefits for the HIV-positive 
individual. Addressing the social and structural factors (inequality in socio-economic status, 
intimate partner violence, etc.) that contribute to gender differences in condom usage, and 
providing HIV-negative women with access to PrEP (which may provide protection in 
settings where condoms cannot be used) are additional strategies which should also be 
pursued.
As has also been seen in other settings, (30) women in our study were more likely to report 
drug equipment sharing than men. However, it seems the relationship between female 
gender and equipment sharing is at least partially explained by demographics, most notably 
employment and income. Female participants in this study were significantly less likely to 
be employed than male participants (31% vs. 49%, p<0.01) and significantly more likely to 
earn a monthly income below the sample median of 20,000 Rubles (68% vs. 44%, p<0.01). 
When there is limited access to clean needles and syringes and/or limited funds to pay for 
new/unused equipment, women may be more likely to share (relative to men). This could be 
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the result of the woman having less (or no) money to pay for the drugs/supplies. These 
patterns have been observed in other populations, including among PWID in South Africa 
where more women (26%) than men (13%) reported always sharing injecting equipment 
(36). Low economic status, coupled with limited work opportunities for women, have also 
been associated with increased sexual risk taking among female (versus male) substance 
users, including having multiple sex partners and relying on sex trade/transactional sex to 
support drug use. Findings from the 2009 National HIV Behavioral Surveillance System, 
conducted in 20 U.S. cities, suggest more female (versus male) PWID have sex in exchange 
for money or drugs (31% and 18%, respectively) (37). Findings from Russia found that 
compared to their male counterparts, female injectors who reported high drug use frequency 
were more likely to also report multiple sex partners (38). Our findings highlight the need 
for free access to clean needles/syringes among women who inject drugs, as well as access 
to opiate agonist therapy to prevent HIV (39).
4.1 Limitations
Our study has limitations. The sample size was relatively modest and participants were 
predominantly male, which limited study power particularly for outcomes that were less 
common (i.e. drug risk behaviors). These findings from Russia might not be representative 
of the relationship between female gender and HIV transmission risk among people who 
inject drugs or have a history of injection drug use, who are living with HIV in other non-
Russian settings, or even within Russia but outside of the Russia ARCH study population. 
Additionally, our research was done with a mixed sample of current and former injection 
drug users.
Another limitation of the current study is that knowledge and perceptions surrounding risk 
of HIV transmission were not assessed, nor did we specifically explore several key 
mechanisms known to contribute to sex and drug use behaviors associated with increased 
risk for HIV transmission. For instance, participants were not asked about their experiences 
of intimate partner violence, despite that it has been associated with women's reduced ability 
to negotiate condom use and talk about HIV prevention with their partner (40). Intimate 
partner violence is also a correlate of drug use and harmful alcohol consumption (41). More 
research is needed to understand the challenges and preferences of HIV-positive women who 
inject (or have a history of injecting) drugs, which may be contributing to their condom 
nonuse and harmful drug and alcohol consumption. A better understanding of the factors 
underlying women's condom choices, or to what extent they have any choice in the matter, 
will inform the design of more meaningful and effective prevention strategies. Furthermore, 
assessing awareness and willingness to use PrEP among HIV-negative women and men who 
have ever injected drugs or have a known HIV-positive partner is needed to inform future 
efforts for HIV prevention.
We also did not assess participants' sexual orientation or gender identity, or these 
characteristics of their sexual partner(s). Further, we did not assess differences in drug use 
and sexual behaviors according to whether the partner under consideration was a long-term 
or casual partner (or a sex worker or stranger). Nor did we measure partner-specific 
information on sexual or drug related behaviors of interest (i.e., that could assess behaviors 
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occurring at the partner-level). Instead, we only measured behaviors of interest at the 
individual level. These details should be collected in future research, as understanding 
partner dynamics contextualizing most at risk situations will help to establish what is needed 
for prevention efforts.
All behavioral measures were self-reported and thus subject to recall and/or social 
desirability biases. Additionally, different timeframes were used for the outcomes (e.g., 
some measured past 30 days while others measured past 90 days) which may have 
differentially impacted participants' ability to accurately remember their true behaviors. 
However, the Russia ARCH cohort study team is skilled at interviewing and has extensive 
experience with this population which likely serves to mitigate this latter bias.
5. Conclusions
Notwithstanding these limitations, this study's findings add to the understanding of the way 
in which gender differences in risk behaviors exist among PLHIV who have ever injected 
drugs in Russia, and offer insights about women's heightened HIV transmission risk in this 
population. Improved knowledge about HIV risk behaviors among both women and men 
who are living with HIV and inject drugs, or have a history of doing so, can support more 
gender-tailored HIV interventions. Further, our results imply that strategies are greatly 
needed in Russia to develop HIV prevention, diagnosis and treatment interventions that take 
into account the influence of sexual behavior and gender. Understanding the way in which 
gender influences whether PLHIV who have ever injected drugs engage in condomless sex, 
and implementing strategies that do not solely rely on condom use (such as TasP and PrEP), 
may lead to more effective HIV control in key populations in Russia and beyond.
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Table I
Baseline demographics, CD4 cell count and substance use overall and by gender among 
HIV-positive people who have ever injected drugs in Russia ARCH, St. Petersburg 
(n=291)
Measure Overall N (%) Female N (%) Male N (%) p-value
Total 291 74 (25.4) 217 (74.5)
Mean age (SD) 33.4 (4.7) 31.5 (4.2) 34.1 (4.8) <0.01
Education beyond primary (>9th grade) 228 (78.4) 56 (75.7) 172 (79.3) 0.52
Employed 130 (44.7) 23 (31.1) 107 (49.3) 0.01
Median monthly income in Rubles (IQR) 20,000 (5,000-30000) 10,000 (4,000-20,000) 20,000 (10,000-30,000) <0.01
Income below median 144 (49.7) 50 (67.6) 94 (43.5) <0.01
Partnered 142 (48.8) 49 (66.2) 93 (42.9) <0.01
Partner HIV status
HIV-negative 51 (17.5) 12 (16.2) 39 (18.0) <0.01
HIV-positive 91 (31.3) 37 (50.0) 54 (24.9)
No partner 149 (51.2) 25 (33.8) 124 (57.1)
Mean CD4 count (SD) 525.1 (305.9) 561.0 (368.2) 512.2 (280.6) 0.32
Opioid and/or Heroin use in past 30 days 118 (40.5) 33 (44.6) 85 (39.2) 0.41
Past 30-day injection drug use 127 (43.6) 34 (45.9) 93 (42.9) 0.64
Among those with past 30 day injection dru g use: drugs injec ted
 Heroin and stimulants 18 (14.2) 6 (17.6) 12 (12.9) 0.75
 Only heroin 96 (75.6%) 25 (73.5%) 71 (76.3%)
 Only stimulants 10 (7.9%) 3 (8.8%) 7 (7.5%)
 Neither 3 (2.4%) 0 (0.0%) 3 (3.2%)
Cannabis use in past 30 days 48 (16.5) 8 (10.8) 40 (18.4) 0.13
Heavy alcohol use in past 30 days 205 (70.4) 58 (78.4) 147 (67.7) 0.08
Transactional sex in past 12 months
Gave money, drugs or alcohol in exchange for sex 30 (10.5%) 0 (0.0%) 30 (14.0%)
Received money, drugs or alcohol in exchange for 
sex
4 (1.4%) 3 (4.2%) 1 (0.5%) <0.01
Gave AND received money, drugs or alcohol in 
exchange for sex
6 (2.1%) 1 (1.4%) 5 (2.3%)
None reported 247 (86.1%) 68 (94.4%) 179 (83.3%)
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Table II
Primary and secondary outcomes at baseline, 12 and 24-month follow-up; and ART use at 
12 and 24-month follow-up, overall and by gender, among HIV-positive people who have 
ever injected drugs in Russia ARCH, St. Petersburg (n=291)
Measure Overall No./N (%) Female no./N (%) Male no./N (%)
Primary Outcomes
Sharing drug equipment past 30 days
Baseline 50/287 (17.4) 16/72 (22.2) 34/215 (15.8)
12 months 35/186 (18.8) 15/50 (30.0) 20/136 (14.7)
24 months 28/133 (21.1) 11/36 (30.6) 17/97 (17.5)
Condomless sex past 90 days
Baseline 133/280 (47.5) 49/70 (70.0) 84/210 (40.0)
12 months 80/179 (44.7) 28/49 (57.1) 52/130 (40.0)
24 months 59/127 (46.5) 21/34 (61.8) 38/93 (40.9)
Secondary Outcomes
Alcohol use prior to sharing past 30 days
Baseline 25/287 (8.7) 7/72 (9.7) 18/215 (8.4)
12 months 13/186 (7.0) 2/50 (4.0) 11/136 (8.1)
24 months 8/133 (6.0) 4/36 (11.1) 4/97 (4.1)
Alcohol use before or during sex past 90 days
Baseline 158/287 (55.2) 45/71 (63.4) 113/215 (52.6)
12 months 79/181 (43.6) 26/50 (52.0) 53/131 (40.5)
24 months 60/131 (45.8) 18/36 (50.0) 42/95 (44.2)
Both drug equipment sharing & unprotected sex
Baseline 30/280 (10.7) 13/70 (18.6) 17/210 (8.1)
12 months 17/179 (9.5) 8/49 (16.3) 9/130 (6.9)
24 months 13/127 (10.2) 8/34 (23.5) 5/93 (5.4)
ART use in the past 6 months
12 months 32/186 (17.2) 10/50 (20.0) 22/136 (16.2)
24 months 46/133 (34.6) 11/36 (30.1) 35/97 (36.1)
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